Table 3.
Events | Entire Cohort (n=165) |
---|---|
| |
Cardiac Event (total) | 12 (7.2) |
LVEF Decline* | 10 (6.1) |
≥ 10% and < LLN | 7 (4.2) |
≥ 16% and ≥ LLN | 3 (1.8) |
Symptomatic heart failure (NYHA class III/IV) | 2 (1.2) |
Cardiac Death | 0 (0) |
| |
Trastuzumab Interruption | |
Cardiac | 7 (4.2) |
Non-cardiac | 11 (6.7) |
Data given as no. (%). NYHA, New York Heart Association.
LVEF decline without severe (NYHA class III/IV) heart failure